Medicine

Lessons from a bad genetics treatment trial for Duchenne muscle dystrophy

.Nature Medication, Published online: 09 October 2024 doi:10.1038/ s41591-024-03316-9Delandistrogene moxeparvovec acquired FDA approval after a damaging test, which highlights the various complexities and obstacles of medication development in this setting.

Articles You Can Be Interested In